ฐานข้อมูลวิจัยด้านสุขภาพจิตและจิตเวช

ผู้วิจัย/Authors: Keshva Pai, Kiran Haridas, K.N.S.Roa, Indrani Poddar, Vikram Haridas.

ชื่อเรื่อง/Title: To Compare the Efficacy, Tolerability and Safety between Memantine and Donepezil in Moderate to Severe Alzheimer’s Disease.

แหล่งที่มา/Source: ASEAN Journal of Psychiatry. Vol. 9, Supplement 1, 26-29 August 2008, page 43-44.

รายละเอียด / Details:

Objective: To compare the efficacy, tolerability and safety between Memantine and Donepezil in moderate to severe Alzheimer’s disease. Methods: It is an open labeled randomized comparative study between Memantine (NMDA receptor atagonist) 20mg/day and Donepezil (cholinesterase inhibitor) 5-10mg/day in Alzheimer’s disease in 22 patients in two equal groups over duration of 28 weeks. The primary efficacy measure was the mean total change in Functional Dementia Scale (FDS) and Care Giver Burden scale (CGBS) using last observation carried forward. Onset of efficacy was defined as> 20% reduction in the mean total score of FDS and CGBS from baseline at 2weeks. Response rate was defined as>50% reduction in the mean total score of FDS and CGBS from baseline to the study end. Tolerability and safely were evaluated by assessing discontinuation rates, adverse event occurrence, vital signs, and laboratory tests. Results: Onset of efficacy on FDS and CGBS was 16.7% (mean time 31.25days) and 80% (mean time 36days) with Memantine and Donepezil respectively. Response rate was 83.3% and 20% with Memantine and Donepezil respectively. Total Reduction in score of FDS from baseline to the study end was 35.50 and 22.60 with Memantine and Donepezil respectively. Total Reduction in score of CBS from baseline to study end was 40.00 and 27.20 with Memantine and Donepezil respectively. Tolerability was 83.33% and 20% with Memantine and Donepezil respectively. Anorexia, muscle cramps, constipation, headache, and insomnia, were the common side effects and self limiting. Safety was 100% in both the groups. Conclusion: Donepezil scored better than Memantine in the onset of efficacy at 2 weeks, however Memantine score better than Donepezil at the end of study (28 weeks) regarding response and improvement in CGBS, FDS and tolerability. Thus, in similar clinical settings Memantine can be preferred.

Keywords: compare the efficacy, tolerability and safety, memantine, donepezil, moderate to severe, alzheimer’s disease

ปีที่เผยแพร่/Year: 2008

Address: Department of Psychiatry, Kasturba Medical College, Manipal University, India

Code: 201000035

ISSN/ISBN: 0218-3420

Country of publication: Thailand

Language: English

Category: Abstract

Download: